Galmed's Colospan reports feasibility data on tissue assessment tool
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology
August 19, 2026 7:00 AM EDTThe prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical centers in Israel. The primary objective was to demonstrate feasibility of intraoperative quantitative measurement of colon tissue quality.The study establishes the clinical foundation for novel intraoperative tissue assessment technology, with an aim to expand Colospan's product pipeline with a second technology platform for Colorectal Surgery.The new technology platform, which complements Colospan's CG-100 intraluminal bypass device, is designed to advance Galmed's strategy to build a leading innovative medtech and... More
